A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects
Primary Purpose
Rabies
Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Changchun Werersai
Jilin Maifeng
Sponsored by
About this trial
This is an interventional prevention trial for Rabies
Eligibility Criteria
Inclusion Criteria:
- Aged from 10 to 60 years old
- Subjects or legal guardians can and will comply with the requirements of the protocol
- Subjects or legal guardians are able to understand and sign the informed consent
- Healthy subjects judged from medical history after investigator's inquiry
- Subjects with temperature <=37.0°C on axillary setting
Exclusion Criteria:
- Female in lactation or pregnancy, or plan to be pregnant during the study period
- Subject who has allergic history to any vaccine or other medicines
- Subject who has injury history by dogs or other mammals and has been vaccinated with rabies vaccine
- Subject who has serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain
- Subject with congenital malformation, developmental disorder or serious chronic disease
- Subject with autoimmune diseases or immunodeficiency
- Subject with asthma, unstable over the past two years requiring emergency treatment, hospitalization, intubation, oral or intravenous corticosteroids
- Subject with diabetes (Type I or II) excluding gestational diabetes
- Subject with thyroidectomy history, or require treatment in the past 12 months due to thyroid disease
- Subject with severe angioedema in the past 3 years or require treatment in the past 2 years
- Subject with hypertension and with a blood pressure exceeding 145/95 mmHg at enrollment time
- Subject with coagulation abnormalities diagnosed by doctors (such as clotting factor deficiency, coagulation disorders, platelet disorder) or obvious bruises or blood clotting disorder
- Subject with cancer, or has been treated in active cancer period or not clearly cured, or may recur during the study period
- Subject with epilepsy, excluding those alcohol epilepsy within three years before quitting drinking or those do not need treatment in the past 3 years
- Asplenia, functional asplenia, without a spleen or removal of the spleen caused by any situation
- Guillain-Barre syndrome
- Any prior administration of immunodepressant or corticosteroids in last 6 months
- Any prior administration of blood products in last 3 months
- Any prior administration of other research medicine/vaccine in last 30 days
- Any prior administration of any attenuated live vaccine in last 30 days
- Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine
- Ongoing anti-tuberculosis prevention or treatment
- Subject who cannot comply with the trial requirements, or with mental illness/ dual-stage affective psychosis in the past or at present; or has not been controlled and needs to take psychiatric drugs the past 2 years; or with suicidal tendencies in the past 5 years
- Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent
Sites / Locations
- Xinyi Center for Disease Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Changchun Werersai
Jilin Maifeng
Arm Description
A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
Outcomes
Primary Outcome Measures
Positive seroconversion rate of serum rabies virus neutralizing antibody 42 days after full vaccination
Secondary Outcome Measures
Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 42 days after full vaccination
Positive seroconversion rate of serum rabies virus neutralizing antibody 14 days after full vaccination
Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 14 days after full vaccination
Incidence of local and systemic adverse reactions during safety observation period after each vaccination
Full Information
NCT ID
NCT02491541
First Posted
July 3, 2015
Last Updated
July 8, 2015
Sponsor
Jiangsu Province Centers for Disease Control and Prevention
1. Study Identification
Unique Protocol Identification Number
NCT02491541
Brief Title
A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects
Official Title
A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu Province Centers for Disease Control and Prevention
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this single-centre, randomized, double-blind, parallel control, phase 3 study is to evaluate the safety and immunogenicity of a rabies vaccine (Vero Cell) for human use in healthy Chinese subjects aged 10-60 years, according to the Essen methods (1-1-1-1-1) vaccination.
Detailed Description
There will be two immunization arms. 1200 healthy subjects will be randomly assigned (1:1) to receive an experimental vaccine or a parallel comparator vaccine. All of them will be received five doses of rabies vaccine at day 0,3,7,14,28 according to the traditional Essen methods (1-1-1-1-1) vaccination.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rabies
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
1200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Changchun Werersai
Arm Type
Experimental
Arm Description
A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
Arm Title
Jilin Maifeng
Arm Type
Active Comparator
Arm Description
A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
Intervention Type
Biological
Intervention Name(s)
Changchun Werersai
Intervention Description
A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
1.0 ml experimental vaccine on day 0,3,7,14,28
Intervention Type
Biological
Intervention Name(s)
Jilin Maifeng
Intervention Description
A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
1.0 ml comparator vaccine on day 0,3,7,14,28
Primary Outcome Measure Information:
Title
Positive seroconversion rate of serum rabies virus neutralizing antibody 42 days after full vaccination
Time Frame
42 days after full vaccination
Secondary Outcome Measure Information:
Title
Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 42 days after full vaccination
Time Frame
42 days after full vaccination
Title
Positive seroconversion rate of serum rabies virus neutralizing antibody 14 days after full vaccination
Time Frame
14 days after full vaccination
Title
Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 14 days after full vaccination
Time Frame
14 days after full vaccination
Title
Incidence of local and systemic adverse reactions during safety observation period after each vaccination
Time Frame
0-7 days after each vaccination and 8-28 days after the fifth vaccination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Aged from 10 to 60 years old
Subjects or legal guardians can and will comply with the requirements of the protocol
Subjects or legal guardians are able to understand and sign the informed consent
Healthy subjects judged from medical history after investigator's inquiry
Subjects with temperature <=37.0°C on axillary setting
Exclusion Criteria:
Female in lactation or pregnancy, or plan to be pregnant during the study period
Subject who has allergic history to any vaccine or other medicines
Subject who has injury history by dogs or other mammals and has been vaccinated with rabies vaccine
Subject who has serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain
Subject with congenital malformation, developmental disorder or serious chronic disease
Subject with autoimmune diseases or immunodeficiency
Subject with asthma, unstable over the past two years requiring emergency treatment, hospitalization, intubation, oral or intravenous corticosteroids
Subject with diabetes (Type I or II) excluding gestational diabetes
Subject with thyroidectomy history, or require treatment in the past 12 months due to thyroid disease
Subject with severe angioedema in the past 3 years or require treatment in the past 2 years
Subject with hypertension and with a blood pressure exceeding 145/95 mmHg at enrollment time
Subject with coagulation abnormalities diagnosed by doctors (such as clotting factor deficiency, coagulation disorders, platelet disorder) or obvious bruises or blood clotting disorder
Subject with cancer, or has been treated in active cancer period or not clearly cured, or may recur during the study period
Subject with epilepsy, excluding those alcohol epilepsy within three years before quitting drinking or those do not need treatment in the past 3 years
Asplenia, functional asplenia, without a spleen or removal of the spleen caused by any situation
Guillain-Barre syndrome
Any prior administration of immunodepressant or corticosteroids in last 6 months
Any prior administration of blood products in last 3 months
Any prior administration of other research medicine/vaccine in last 30 days
Any prior administration of any attenuated live vaccine in last 30 days
Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine
Ongoing anti-tuberculosis prevention or treatment
Subject who cannot comply with the trial requirements, or with mental illness/ dual-stage affective psychosis in the past or at present; or has not been controlled and needs to take psychiatric drugs the past 2 years; or with suicidal tendencies in the past 5 years
Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yuemei Hu
Organizational Affiliation
Jiangsu Provincial Center for Diseases Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xinyi Center for Disease Control and Prevention
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221400
Country
China
12. IPD Sharing Statement
Learn more about this trial
A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects
We'll reach out to this number within 24 hrs